Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · S-3ASR

Amneal Pharmaceuticals, Inc.

AMRXNASDAQEQUITYCurrent

SEC Filing

Filed Sep 3, 2026Accepted Sep 3, 2026, 4:44 PM EDTCIK 1723128Accession 0001140361-26-035617
Share

Company context

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Current securities

Recent company filings

  1. 4 filingSep 21, 2026
  2. 4 filingSep 14, 2026
  3. 4 filingSep 2, 2026
  4. 4 filingAug 25, 2026
  5. 4 filingAug 13, 2026

As-filed source

Primary evidence